Gossamer Bio Inc (GOSS) concluded trading on Wednesday at a closing price of $1.66, with 4.13 million shares of worth about $6.86 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 79.87% during that period and on July 16, 2025 the price saw a gain of about 14.48%. Currently the company’s common shares owned by public are about 227.22M shares, out of which, 182.66M shares are available for trading.
Stock saw a price change of 22.06% in past 5 days and over the past one month there was a price change of 33.87%. Year-to-date (YTD), GOSS shares are showing a performance of 41.88% which increased to 83.51% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.66 but also hit the highest price of $1.55 during that period. The average intraday trading volume for Gossamer Bio Inc shares is 1.94 million. The stock is currently trading 23.88% above its 20-day simple moving average (SMA20), while that difference is up 34.00% for SMA50 and it goes to 58.36% higher than SMA200.
Gossamer Bio Inc (NASDAQ: GOSS) currently have 227.22M outstanding shares and institutions hold larger chunk of about 58.38% of that.
The stock has a current market capitalization of $377.32M and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$0.24 in the same period. It has Quick Ratio of 5.71. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GOSS, volatility over the week remained 9.18% while standing at 8.00% over the month.
Stock’s fiscal year EPS is expected to drop by -169.82% while it is estimated to increase by 31.68% in next year. EPS is likely to shrink at an annualized rate of 19.90% for next 5-years, compared to annual growth of 40.29% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on July 14, 2025 offering a Sector outperform rating for the stock and assigned a target price of $11 to it. Coverage by Oppenheimer stated Gossamer Bio Inc (GOSS) stock as an Outperform in their note to investors on June 25, 2024, suggesting a price target of $9 for the stock. On April 05, 2024, Wedbush Resumed their recommendations, while on July 27, 2023, UBS Downgrade their ratings for the stock with a price target of $1.25. Stock get a Mkt perform rating from Raymond James on March 07, 2023.
